2019 On-Demand: Full Access (Sat-Tues Sessions)


By far the best value to watch all the available sessions from the 2019 AABB Annual Meeting and earn continuing education credit. This package includes 121 sessions which are eligible for up to:

  • 150.5 General Participation credits
  • 127.25 Continuing Medical Education credits (CME) for physicians
  • 43.75 SAM credits
  • 138.50 California Lab Personnel, Florida Lab Personnel or California Nurse contact hours.

If purchasing each session individually the cost is $2,370/$2,970 (member/nonmember). Access is available through December 31, 2021 so purchase this package today.

Residents/Fellows/Students - take an additional $100 off this package price if you email a signed a letter from your institution/Program Director and/or current student transcript verifying your status to eLearning@aabb.org. 

Please note: On-Demand presentations do not include opening and closing sessions, industry workshops or the SBB/BB Exam Review Session Study Guide. Presentations are available at the discretion of the speakers and subject to change without notice.

Members: $499.00
Standard: $599.00

Products

ST1-01: Hear Ye! Hear Ye! Debate on the Big Topics in Blood Use in Trauma Resuscitation

Preview Available

ST1-01: Hear Ye! Hear Ye! Debate on the Big Topics in Blood Use in Trauma Resuscitation

Oct 19, 2019 8:00am ‐ Oct 19, 2019 9:30am
Expiration Date: Dec 31, 2021

Credits: None available.

The literature on blood product use in trauma is growing and providing data to guide the practice. Many different areas of research are now underway, from the ideal resuscitation fluids, to the nature of the products to be used, to novel storage mechanisms for conventional products...just about everything surrounding blood product use in trauma resuscitation is up for discussion. Many well designed studies have reported their findings, while some aspects of the practice are less well investigated. The session will start with a description of the epidemiology of trauma in the USA and around the world. The scene will then be set for a moderated debate between two experts on a variety of hot topics in blood product use in trauma resuscitation.

The first speaker will be Dr. Brian Eastridge who will set the scene for the debate by providing an important talk on the epidemiology of trauma. Why are so many resources being focused on this topic? Where is trauma occurring - is it all on highways and battlefields? How many lives can we impact with improved resuscitation strategies? How can the epidemiological data on trauma help us plan for better management?

The next talk will feature a moderated debate between two well informed speakers. Dr. Phil Spinella and Dr. Richard Haspel will answer questions posed by Dr. Mark Yazer covering a variety of topics - are cold platelets really better than warm platelets? What's the evidence for using whole blood in trauma resuscitation? How safe is tranexamic acid? Should we used fixed ratio blood product resuscitation strategies from the time the bleeding starts until it ends? What is the role of point of care testing in trauma resuscitation? Each speaker will prepare a short, pre scripted answer to each question, and then Drs. Spinella and Hapsel will debate with each other, and the audience will be encouraged to participate and share their perspectives and have their questions answered by these experts. Differences of opinion will be welcomed and a lively discussion is sure to ensue.

At the completion of this session, participants should be able to:

  • Appreciate the scope and magnitude of traumatic deaths in the USA and around the world, and the extent to which many could have been prevented
  • Compare and contrast different approaches to blood product use in trauma patients through a moderated debate
  • Plan their own approach to the care of these patients based on the outcome of the debate

Speaker(s):
  • Mark H. Yazer, MD, Department of Pathology, University of Pittsburgh
  • Philip C. Spinella, MD, FCCM, Washington University in St. Louis, Pediatrics Critical Care Dept.
  • Brian Eastridge, MD, University of Texas Health Science Center San Antonio
  • Richard L. Haspel, MD, PhD, Medical Director, Beth Israel Deaconess Medical Center
Standard: $25.00
Members: $20.00

ST1-10: Practical Considerations in Directing an Apheresis Service

Preview Available

ST1-10: Practical Considerations in Directing an Apheresis Service

Oct 19, 2019 8:00am ‐ Oct 19, 2019 9:30am
Expiration Date: Dec 31, 2021

Credits: None available.

Apheresis has been a treatment modality for many conditions. Additionally, it can be used to collect cells for use in hematopoietic progenitor cell transplantations or for further manufacturing into other cellular therapy products for the treatment of malignancy, such as chimeric antigen receptor T cells. The complexity of an apheresis operation is increased dramatically than ever before and thus, the management of this service is often challenging. In this session, key practical considerations to successfully directing an apheresis service will be discussed. Specifically, since having good access is critical to an effective and safe apheresis procedure, different access options for both inpatient and outpatient populations will be discussed and compared. Given many apheresis collection products are considered therapeutic agent and to ensure their efficacy and safety during treatments, they are highly regulated by both the FDA and other accrediting agencies. Therefore, this session will also provide a brief review of basic regulatory standards along with basic principles in equipment validation and management in the field of apheresis. Lastly, medical coding terminology and the reimbursement process in apheresis will be explained to ensure proper and successful billing and communication with third party payers.

Learning Objectives:

  • Review basic of regulations, validation, and quality management in an apheresis service.
  • Discuss and compare several options for access, as well as trouble-shooting for patients undergoing apheresis procedures.
  • Explain medical coding terminology and examine the reimbursement process in apheresis.

Please note: Huy Pham, MD, MPH did not consent to be recorded; therefore, the on-demand presentation and handout have been modified accordingly.

Speaker(s):
  • Jan C. Hofmann, MD, MPH, MSc, Department of Laboratory Medicine, UCSF School of Medicine
  • Lawrence A. Williams, Department of Pathology, University of Alabama at Birmingham; UAB
Standard: $25.00
Members: $20.00

ST1-05: How Severe Is This Donor Reaction? International Validation of a Severity Grading Tool-Putting It into Practice

Preview Available

ST1-05: How Severe Is This Donor Reaction? International Validation of a Severity Grading Tool-Putting It into Practice

Oct 19, 2019 8:00am ‐ Oct 19, 2019 9:30am
Expiration Date: Dec 31, 2021

Credits: None available.

Great News! The work is all done, the Donor Adverse Event Severity Grading Tool developed by the AABB Donor Biovigilance group has been validated by national and international experts and users. It is time to put the finished product to the test. Come test your skill assigning Severity Grades using the new tool to grade cases used in the validation study and see how you compare with the experts. You will also be the first to see the data produced by the validation, glean perspective from international hemovigilance experts in their use of the tool, and provide valued feedback!

Learning Objectives:

  • Review the Donor Adverse Event Severity Grading Tool and identify attributes assigned to each Grade.
  • Apply the Grading Tool to determine Severity of validation cases.
  • Summarize the major findings of the validation.
  • Report the experiences of the international hemovigilance community in their use of the Tool.
  • Produce feedback and make recommendations for future refinements.

Speaker(s):
Standard: $25.00
Members: $20.00

ST1-06: Understanding Human Error for Improved Transfusion Safety

Preview Available

ST1-06: Understanding Human Error for Improved Transfusion Safety

Oct 19, 2019 8:00am ‐ Oct 19, 2019 9:30am
Expiration Date: Dec 31, 2021

Credits: None available.

This session will discuss the debate about the prevalence and types of error in medicine (cognitive bias, systems failures, other) and how such error impacts patient safety, as well as controversial strategies for mitigating error. We will discuss the types and contribution of human errors in transfusion medicine. We review the current literature on sample collection and patient registration errors, and evaluate the use of near-patient electronic positive patient identification to reduce these errors.

Learning Objectives:

  • Discuss the prevalence and types of error - systems failures, cognitive bias, other- that occur in medicine and how such error impacts patient safety and the feasibility of cognitive debiasing strategies in mitigating error.
  • Report the current rates of sample collection errors and the impact of near-patient electronic positive patient identification on reducing errors.
  • Analyze the prevalence and types of errors that occur during patient registration that threaten transfusion safety.

Speaker(s):
  • Quentin Eichbaum, MD, PhD, MPH, MFA, MMHC, FCAP, FASCP, Professor of Pathology & Medical Education, Co-Director, Transfusion Medicine, Vanderbilt University Medical Center
  • Jeannie Callum, MD, FRCPC, Transfusion Medicine Specialist and Hematologist, Sunnybrook Health Sciences Centre
  • Richard M. Kaufman, MD, Medical Director, Brigham and Women's Hospital
Standard: $25.00
Members: $20.00

ST1-02: Red Blood Cell Storage: The Oxygen Paradox

Preview Available

ST1-02: Red Blood Cell Storage: The Oxygen Paradox

Oct 19, 2019 8:00am ‐ Oct 19, 2019 9:30am
Expiration Date: Dec 31, 2021

Credits: None available.

Red blood cells are solely responsible for supplying oxygen for mitochondrial metabolism in all the tissues of the body. This critical role has led to the ubiquitous use of red blood cells as a foundation for modern healthcare systems resulting in over 100 million units of blood prescribed globally to improve the oxygen carrying capacity of patients in need. In the body the red cell is uniquely equipped to juggle oxygen and the iron(II) atom in hemoglobin. However, upon storage, physiology is replaced by chemistry. In the presence of an uncontrolled abundance of oxygen the iron(II) is oxidized to iron(III) initiating a cascade of changes during storage that are attributed to oxidative damage which is dependent on the ability of the cell to protect itself from such oxidative damage. Degradation during storage reduces the ability of red blood cells to carry and to deliver oxygen and creates non-red cell by-products that are associated with adverse effects, and do not deliver oxygen; these by-products are transfused along with the red cells. A salient example is the unintended dose of free iron made available to patients under some transfusion conditions that is associated with adverse outcomes such as iron overload and infections.

Learning Objectives:

  • Restate the role oxidative damage plays and the drivers that contribute to changes in red cell physiology during refrigerated storage.
  • Recognize the changes in red cell quality caused by oxidative damage as measured by current techniques.
  • Question the effects of oxidative damage and the role it plays on red cell quality, specifically in assessing successful patient treatment and expected outcomes
  • Identify donor- and process-related red cell characteristics which could mitigate oxidative damage and potential risk to patients.
  • Hypothesize potential opportunities, both short and long term, to improve red cell quality and resulting patient outcomes.

Please note: Angelo D'Alessandro, PhD did not consent to be recorded; therefore, the on-demand presentation and handout have been modified accordingly.

Speaker(s):
Standard: $25.00
Members: $20.00

ST1-04: Paternity Testing & Human Identification: How methods developed for blood banking led to advances in criminal investigations and vice versa

Preview Available

ST1-04: Paternity Testing & Human Identification: How methods developed for blood banking led to advances in criminal investigations and vice versa

Oct 19, 2019 8:00am ‐ Oct 19, 2019 9:30am
Expiration Date: Dec 31, 2021

Credits: None available.

Clinical and forensic molecular biology laboratories utilize some of the same chemistry, software and instrumentation that produce test data to determine human identity. Research and clinical laboratory testing have advanced the field of forensic casework and vice versa. In the first presentation, we will survey the field of clinical molecular testing over the past 25 years, highlighting technical innovations that have led to testing familiar to most of us, including: engraftment monitoring for bone marrow transplantation, chimerism testing for transfusion-associated GVHD analysis, and parentage testing. In the second presentation, we will examine forensic identity testing through case studies using advanced technologies, such as: next generation sequencing, bioinformatics, mixture deconvolution and probabilistic genotyping. Finally, we will explore future directions for clinical and forensic laboratories using advanced technologies.

Learning Objectives:

  • Discuss the similarities in molecular testing performed in clinical and forensic laboratories.
  • Summarize advances made possible by the knowledge gained from the sequencing of a million human genomes.
  • Describe software tools to consider in both clinical and forensic disciplines.

Speaker(s):
  • Patricia Kopko, MD, Professor of Pathology, Director of Transfusion Medicine, Associate Director, Immunogenetics and Transplantation Laboratory, Associate Director, Pathology Residency Training Program, University of California, San Diego
  • Carol Pancoska, Ph.D.
  • Rhonda Kay Roby, Ph.D., M.P.H., Alameda County Sheriff's Office Crime Laboratory
Standard: $25.00
Members: $20.00

ST1-07: Men Who Have Sex with Men (MSM): Transforming Policies Around the Globe

Preview Available

ST1-07: Men Who Have Sex with Men (MSM): Transforming Policies Around the Globe

Oct 19, 2019 8:00am ‐ Oct 19, 2019 9:30am
Expiration Date: Dec 31, 2021

Credits: None available.

In 2016 the FDA Guidance “Revised recommendations for reducing the risk of human immunodeficiency virus transmission by blood and blood products” permitted MSM to donate if they have not had sex with a man in the last 12 months (formerly not permitted if “since 1977”). There has now been enough time to evaluate the impact of this change. Currently many countries with 12 month deferrals have either moved to policies that are less restrictive (shorter time-deferrals or permitting some low-risk MSM to donate without a time deferral) or are considering doing so. This session will delve into the evidence considered when making these policy decisions, and evaluate the safety and sufficiency of the blood supply post-implementation. In this session the AABB Donor History Task Force and the International Society for Blood Transfusion Transfusion-Transmitted Infectious Diseases Working Party will present the following:

  • A description of the range of policies that address blood donation for MSM including time-deferrals, plasma quarantine strategies and alternative risk questions. Examples of policies in a range of different countries will be presented.
  • With 2 years since implementing the 12 month deferral in the USA, data and risk assessment pre-implementation and data evaluating the safety impact post-implementation will be presented.
  • With almost 2 years since implementing a 3 month deferral in the United Kingdom, data and risk assessment pre-implementation will be described as well the post-implementation evaluation.
  • Data considered when evaluating a proposal to decrease deferral from 12 months to 3 months in Canada will be described. Current research relating to assessment of other potential policies that could permit some low risk MSM to donate without time deferral in Canada will be discussed.

Learning Objectives:

  • Describe a range of policies that address blood donation for Men Who Have Sex with Men (MSM) including time-deferrals, plasma quarantine strategies and alternative risk questions.
  • Differentiate MSM donor policies in the US, the UK and Canada.
  • Explain research approaches intended to provide data to inform further changes to MSM donor policy.

Speaker(s):
Standard: $25.00
Members: $20.00

ST1-08: Developing a Training Program for Future Cellular Therapy Professionals

Preview Available

ST1-08: Developing a Training Program for Future Cellular Therapy Professionals

Oct 19, 2019 8:00am ‐ Oct 19, 2019 9:30am
Expiration Date: Dec 31, 2021

Credits: None available.

The rapidly growing field of cellular therapy faces a major challenge in the availability of qualified professionals. From technologists to laboratory directors, the current training environment simply has not kept up with the rapid expansion and the novel nature of this exciting new field. Regular medical technologists lack the experience in a current Good Manufacturing Practice (cGMP) environment. Most transfusion medicine trainees have little exposure to the field of cellular therapy, whether it is standard of care, or investigational. There are currently no accredited cellular therapy fellowships by the Accreditation Council for Graduate Medical Education (ACGME). 

This session intend to showcase some of the existing cellular therapy programs, from short to long ones. It aims to bring to the audience's attention currently available, albeit limited, training opportunities in cellular therapy. Furthermore, it also hopes to stimulate attendee's own desire to bring such need back to their own institutions and perhaps design a training program of their own. Only with a pipeline of well trained professionals can this field truly achieve its potential.

Learning Objectives:

  • Appreciate the lack of training opportunities in cellular therapy.
  • Identify currently available training programs in cellular therapy.
  • Design their own training program, depending on the trainees targeted and scope/resources available.

Speaker(s):
Standard: $25.00
Members: $20.00

ST1-09: Bioprinting: Translational Pathway to the Clinic (AABB/TERMIS-AM Joint Session)

Preview Available

ST1-09: Bioprinting: Translational Pathway to the Clinic (AABB/TERMIS-AM Joint Session)

Oct 19, 2019 8:00am ‐ Oct 19, 2019 9:30am
Expiration Date: Dec 31, 2021

Credits: None available.

Bioprinting has become an innovative tool for tissue engineering and regenerative medicine. This technology has been developed to allow construction of biological substitutes mimicking structures and functions of native tissues or organs. 3D Bioprinting enables precise placement of various cell types, biomaterials, and bioactive molecules in a single three-dimensional (3-D) architecture. This session will provide insights into the rapidly developing area of bioprinting and how this technology is being developed for clinical applications as well as the regulatory considerations.

Learning Objectives:

  • Discuss the fundamentals of Biofabrication.
  • Discuss the current status of regulatory oversight.
  • Describe how bioprinting technology is translated into the clinic.

Please note: James Yoo, MD, PhD did not consent to be recorded; therefore, the on-demand presentation and handout have been modified accordingly.

Speaker(s):
Standard: $25.00
Members: $20.00

ST2-11: Ask the Standards

Preview Available

ST2-11: Ask the Standards

Oct 19, 2019 10:00am ‐ Oct 19, 2019 11:30am
Expiration Date: Dec 31, 2021

Credits: None available.

Presentations will be given by standards committee chairs who have new or revised editions to discuss. Questions for the discussion are to be submitted before the scheduled session via the AABB website starting late August, at kiosks in the Cyber Connection located in the Henry B. González Convention Center in San Antonio, and during the session.

At the completion of this session, participants should be able to:

  • Review new and changed standards for newly issued sets of Standards
  • Explain the Standards Creating and Setting Process
  • Explain the difference between Standards and Guidance

Speaker(s):
Standard: $25.00
Members: $20.00
Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content